|Bid||4,420.00 x 6100|
|Ask||4,540.00 x 13000|
|Day's Range||4,439.50 - 4,507.50|
|52 Week Range||3,996.00 - 5,520.00|
|PE Ratio (TTM)||16.84|
|Dividend & Yield||2.79 (4.97%)|
|1y Target Est||N/A|
AstraZeneca PLC is betting that technology from German startup Ethris GmbH will help it add to its stockpile of treatments for respiratory diseases.
Champions Oncology Inc. shares surged 8.2% in premarket trade Monday on news of the company's collaboration with AstraZeneca . The companies plan to develop new Patient-Derived Xenograft (PDX) models -- ...
The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.